FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> molecules | combination | Merck KgAA

Merck KGaA starts Phase III Parkinson's trial

Tools

Merck KGaA has launched a late-stage study of safinamide for Parkinson's disease. The drug is designed to help improve motor function, but the study will also explore its affect on cognitive function and quality of life. Some 650 volunteers are being signed up to get two doses of the drug in combination with dopamine agonists in comparison to dopamine agonists alone. Merck gained a worldwide license to the therapy from Newron last year.

- see this release
- here's the AFX report on the trial

Related Articles:
More tests planned after Parkinson's drug fails trial. Report
New approaches pursued on Parkinson's. Report
Molecule could reverse Parkinson's. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:
Be the first to comment
More stories about molecules   combination   Merck KgAA  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.